Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 11/20 | 0.65 |
| ▸ | MMP12 | P39900 | 4/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1596230 | 1.00 | BMP1 (0.65) | BMP1MMP12DPP4DPP9CHRNA7 | |
| SCHEMBL4583761 | 1.00 | BMP1 (0.65) | BMP1MMP12DPP4DPP9CHRNA7 | |
| SCHEMBL1596984 | 0.87 | ALDH1A1 (0.47) | BMP1MMP12ALDH1A1HPGD | |
| SCHEMBL1596987 | 0.87 | ALDH1A1 (0.47) | BMP1MMP12ALDH1A1HPGD | |
| SCHEMBL1596978 | 0.87 | ALDH1A1 (0.47) | BMP1MMP12ALDH1A1HPGD | |
| SCHEMBL2783859 | 0.85 | BMP1 (0.60) | BMP1MMP12DPP4DPP9CHRNA7 | |
| SCHEMBL2783856 | 0.85 | BMP1 (0.60) | BMP1MMP12DPP4DPP9CHRNA7 | |
| SCHEMBL1595933 | 0.77 | BMP1 (0.41) | BMP1MMP12 | |
| SCHEMBL1595935 | 0.77 | BMP1 (0.41) | BMP1MMP12 | |
| SCHEMBL4582906 | 0.77 | BMP1 (0.41) | BMP1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | claimed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | claimed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | MRPL21, NRDC, SPOUT1 | BMP1 1513/4885MMP12 332/4885DPP4 79/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | BMP1 1590/4885MMP12 1436/4885DPP4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.